Life Sciences, Healthcare & Pharmaceuticals
Health & Life Sciences - IP and Technology
The Health Technologies and Life Sciences Regulation Department offers comprehensive regulatory legal services to companies and entities acting in the health and life sciences field. The department specializes in the legal aspects of regulatory classification of health products, registration, licensing, manufacturing, importation, distribution, marketing, labeling, sales promotion, advertisement, pricing and reimbursement of pharmaceutical products, medical devices and consumer products.
In addition, the team has significant expertise in all fields of healthcare legislation, including the National Health Insurance Act, the Patients' Rights Act, the People's Health Ordinance, clinical trial regulation, medical institute regulation and the legislation regulation the medical practice and the para-medical practices. We also have specific expertise in general fields of law which impact the healthcare field, such as the Freedom of Information Act, The Liability for Defective Products Act, privacy protection law, consumers' rights law, broadcasting law, internet law, etc.
The department offers Herzog Fox & Neeman's clients full legal services in said fields, including ongoing legal counselling on regulatory matters, preparation of written legal opinions in Hebrew or English, representation before governmental authorities and parliamentary committees and drafting legislation bills and guidelines proposals in the healthcare field. The team has extensive experience representing multinational companies and is uniquely acquainted with their needs. The Department also provides assistance on regulatory aspects of the commercial activity of Herzog Fox & Neeman's clients, in matters such as drafting distribution, agency, quality, pharmacovigilance and all relevant clinical trial agreements.
The Department's in-depth familiarity with applicable legal provisions and the common practice, its close relationship with decision makers as well as its reputation among the healthcare authorities, often enables it to reach amicable solutions for disagreements with the authorities, while avoiding the need for lengthy and risky legal procedures. The lawyers in the department have reached considerable achievements in discussions with the health authorities, which, in many cases, have led to changes in the Authorities' decisions, the publication of new guidelines and/or the modification of existing ones.
The department is focused on reaching amicable solutions for disputes between Herzog Fox & Neeman's clients and the regulatory authorities. However, when such solutions may not be found, the department offers comprehensive legal representation before administrative courts, including the High Court of Justice and the District Courts of Administrative Affairs. The team is also experienced in arguing at all levels of substantial law, from constitutional law to internal guidelines and common practice, as well as has a thorough familiarity with the special procedures before the administrative institutions. Throughout the years, the department's lawyers have been involved in the most significant cases of healthcare regulatory affairs that have been heard by the Supreme Court.
Health & Life Sciences - IP and Technology News & Insights
Happy Holidays! Wishing you and your loved ones health and happiness in the new year. May 2023 be an extraordinary
Happy Holidays !
Our Client, TelCann LTD, a licensed medical cannabis cultivator, has signed a substantial agreement with Canonic, a company focused on
Our Client TelCann LTD, has signed a substantial agreement with Canonic.
We want to thank you all for tackling the challenges of 2020 with us and hope that in 2021 we
Have a Happy and Healthy New Year 2021
As you know, Israel continues its efforts to deal with the Corona Virus and contain it, to avoid its spreading
Handling the Corona Virus- Live Updates
Herzog Fox & Neeman Partners Yair Geva, Tomer Farkash, Dan Sharot, and Ofer Granot, together with Associate Michal Shirin, represented Israeli biopharmaceutical company Entera Bio
Herzog Fox & Neeman Represents Entera Bio in $270m Amgen Licensing Deal
On the 18th of June, 2018, the Ministry of Health published a circular pertaining to the rules for the commercial
Client Update | Rules for Commercial Engagements of Health Institutions
During the first half of 2018, four amendments to the legislation on cost-control of drug pricing [of preparations] in Israel
Client Update | Changes in Cost-Control Drug Pricing Policy | June 2018
BDI Code has published its 2018 Israel Legal Rankings, where, once again, our firm has been ranked the leading Israeli
BDI Code’s Ranking for 2018: Herzog Fox & Neeman ranked leading law firm in Israel!
Dear clients and friends, In Israel, health information is constantly being processed and recorded on a large scale, and due
Client Update | New Regulation on the Use of Health Data for Research and Commercial Purposes
The 24th Amendment of the Pharmacists Ordinance [New Version], 1981, effective as of October 2016, introduced a major reform in the enforcement